ReviewMultiple sclerosis international2016
Management of Multiple Sclerosis in the Breastfeeding Mother.
Review in Multiple sclerosis international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Transfer of monoclonal antibodies into breastmilk in neurologic and non-neurologic diseases.Neurology(R) neuroimmunology & neuroinflammation · 2020Pooled it
- Assessing Breastfeeding Attitudes and Self-Efficacy Among Health care Personnel and Women With Multiple Sclerosis: Two Cross-Sectional Surveys.Brain and behavior · 2025Article
- Coupling Pre- and Postnatal Infant Exposures with Physiologically Based Pharmacokinetic Modeling to Predict Cumulative Maternal Levetiracetam Exposure During Breastfeeding.Clinical pharmacokinetics · 2024Article
- Patient-centered pregnancy planning in multiple sclerosis: evidence for a new era.Arquivos de neuro-psiquiatria · 2024Review
- Personalized Use of Disease-Modifying Therapies in Multiple Sclerosis.Pharmaceutics · 2024Review
- Very low monomethyl fumarate exposure via human milk: a case report-a contribution from the ConcePTION project.Frontiers in public health · 2024Article
- [Esclerosis multiple. Lactancia. Lactante. Planificacion familiar. Posparto. Tratamiento modificador de la enfermedad.]Revista de neurologia · 2023Review
- Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis - COBRA study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Article
- The protective role of breastfeeding in multiple sclerosis: Latest evidence and practical considerations.Frontiers in neurology · 2022Review
- Disease-Modifying Drugs and Breastfeeding in Multiple Sclerosis: A Narrative Literature Review.Frontiers in neurology · 2022Review
- Updated Perspectives on the Challenges of Managing Multiple Sclerosis During Pregnancy.Degenerative neurological and neuromuscular disease · 2022Review
- Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations.Journal of drug assessment · 2020Article
- An Update on the Use of Disease-Modifying Therapy in Pregnant Patients with Multiple Sclerosis.CNS drugs · 2018Review
- Pregnancy: Effect on Multiple Sclerosis, Treatment Considerations, and Breastfeeding.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple Sclerosis (MS) is an autoimmune neurological disease characterized by inflammation of the brain and spinal cord. Relapsing-Remitting MS is characterized by acute attacks followed by remission. Treatment is aimed at halting these attacks; therapy may last for months to years. Because MS disproportionately affects females and commonly begins during the childbearing years, clinicians treat pregnant or nursing MS patients. The intent of this review is to perform an in-depth analysis into the safety of drugs used in breastfeeding women with MS. This paper is composed of several drugs used in the treatment of MS and current research regarding their safety in breastfeeding including immunomodulators, immunosuppressants, monoclonal antibodies, corticosteroids, and drugs used for symptomatic treatment. Typically, some medications are large polar molecules which often do not pass into the milk in clinically relevant amounts. For this reason, interferon beta is likely safe for the infant when given to a breastfeeding mother. However, other drugs with particularly dangerous side effects may not be recommended. While treatment options are available and some data from clinical studies does exist, there continues to be a need for investigation and ongoing review of the medications used in breastfeeding mothers.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.